24/7 Market News Snapshot 17 January, 2025 – Autonomix Medical, Inc. Common Stock (NASDAQ:AMIX)

January 17, 2025

DENVER, Colo., 17 January, 2025 (247marketnews.com) – (NASDAQ:AMIX) are discussed in this article.
Autonomix Medical, Inc. (NASDAQ:AMIX) is witnessing a notable upswing in its pre-market trading, currently positioned at $3.207, boasting a considerable increase of 12.13% from the prior close of $2.860. This surge in stock price is indicative of a robust market response, likely fueled by the recent announcement of a significant technological breakthrough. The company has achieved a crucial milestone with the “design lock” of its Application Specific Integrated Circuits (ASIC) microchip, marking a pivotal moment in its journey toward initiating a pivotal clinical trial in the United States aimed at addressing pancreatic cancer pain.

The trading activity has also seen a substantial volume of 2.80 million shares, reflecting strong investor confidence amid heightened market interest. CEO Brad Hauser highlighted that achieving design lock is more than a technical milestone; it reinforces the company’s dedication to advancing diagnostics and treatments for nerve-related diseases. The ASIC microchip plays a vital role in Autonomix’s intellectual property portfolio, capable of detecting minute nerve signals through the vasculature.

This innovative technology aims to provide an effective solution for pain management in pancreatic cancer patients, a demographic that faces significant challenges related to debilitating pain. The Autonomix Sensing and RF Ablation System introduces a transformative opportunity that could revolutionize treatment approaches. With its unique capacity for sensitivity—approximately 3,000 times greater than current alternatives—this platform holds promise for various medical fields, including cardiology and chronic pain management.

As Autonomix Medical progresses toward its Investigational Device Exemption (IDE) submission, the company remains committed to harnessing cutting-edge technology to enhance patient outcomes, signaling a hopeful advance in the treatment of nerve-related pain and other medical conditions. Further developments will be communicated as the clinical phase unfolds.

Related news for (AMIX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.